KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Gains from Investment Securities: 2017-2025

Historic Gains from Investment Securities for Aquestive Therapeutics (AQST) over the last 7 years, with Sep 2025 value amounting to $70,000.

  • Aquestive Therapeutics' Gains from Investment Securities fell 65.35% to $70,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $793,000, marking a year-over-year decrease of 25.54%. This contributed to the annual value of $1.1 million for FY2024, which is 439.71% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Gains from Investment Securities stood at $70,000, which was up 108.72% from -$803,000 recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Gains from Investment Securities ranged from a high of $1.5 million in Q1 2025 and a low of -$803,000 during Q2 2025.
  • Moreover, its 3-year median value for Gains from Investment Securities was $7,000 (2023), whereas its average is $190,636.
  • Data for Aquestive Therapeutics' Gains from Investment Securities shows a peak YoY increase of 821.43% (in 2024) and a maximum YoY decrease of 1,600.00% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Aquestive Therapeutics' Gains from Investment Securities stood at $51,000 in 2021, then soared by 119.61% to $112,000 in 2022, then crashed by 131.25% to -$35,000 in 2023, then soared by 102.86% to $1,000 in 2024, then crashed by 65.35% to $70,000 in 2025.
  • Its Gains from Investment Securities stands at $70,000 for Q3 2025, versus -$803,000 for Q2 2025 and $1.5 million for Q1 2025.